Pharmacovigilance of drugs not inhaled in hospitalized patients with broncopulmonar disease

Main Article Content

Beatriz Espinosa-Franco
Ma. de Lourdes García Guillén

Abstract

It is known that all medicines can cause adverse reactions. This reactions rank from moderate to severe adverse reactions which can risk patient life. To detect the presence of adverse reactions of not inhaled drugs in hospitalized patients at a Chronic Obstructive Pulmonary Disease (COPD) clinic as well as severity and causality, a prospective and transversal study was performed from January to October of 2006. The patients were monitored from their admission to their egress, asking the patients, ckecking their clinical history and their nursery inform, making a daily diagnostic, treatment and potential adverse reactions registry. The adverse reaction definition proposed by WHO was used. Descriptive statistic was applied. Overall, 60 (29.4%) adverse drug reaction were detected in 204 hospitalized patients in this period. 65% were men and 35% were women with average age of 59.53 years and a 19 days average stay at hospital, with and average number of prescribed drugs of 9. The 46.7% with COPD (VEF1 40.12% y VEF1/CVF 61.93%), asthma 15%, pneumonia 8.3% and others. The implicated drugs were: methylprednisolone 26.67%, ceftriaxone 8.33%, ciprofloxacin 10% and heparin 11.67%. About the severity it was found that 7.14% were mild, 87.14% were moderately and 5.71% serious. It was found that a higher percentage of adverse reactions were developed in these patients than those reported at international level.

Article Details

How to Cite
Espinosa-Franco, B., & García Guillén, M. de L. (2011). Pharmacovigilance of drugs not inhaled in hospitalized patients with broncopulmonar disease. Vertientes. Revista Especializada En Ciencias De La Salud, 14(1). Retrieved from https://journals.unam.mx/index.php/vertientes/article/view/26698